Pacira BioSciences, Inc. has completed its merger with Viatris Inc., marking a significant transition for the company and its stakeholders. The merger was finalized on November 17, 2026, with each share of Pacira being converted into a cash payment of $36.50 per share. This development is crucial as it reshapes the ownership structure of Pacira and may influence the competitive landscape within the pharmaceutical preparations industry.
Background
Pacira BioSciences, Inc. operates in the pharmaceutical preparations sector, specifically focusing on innovative treatments. The company trades under the ticker symbol PCRX on the Nasdaq exchange. Recent filings indicate that Pacira has undergone several changes, including a name change from Pacira Pharmaceuticals, Inc. in 2010.
What the Filing Says
The recent SEC filing reveals that Kristen Williams, the Chief Administrative Officer, reported significant transactions related to the merger. Williams disposed of 167,062 shares of Pacira's common stock as part of the merger agreement. The filing notes, "Disposed of pursuant to the Agreement and Plan of Merger..." indicating the completion of the merger process.
Impact
This merger may significantly affect employees, shareholders, and the broader pharmaceutical industry. As Pacira becomes a wholly owned subsidiary of Viatris, stakeholders will need to adjust to the new corporate structure and strategic direction. The merger could also prompt competitors to reevaluate their strategies in response to the consolidation in the pharmaceutical preparations sector.
What's Next
The filing does not specify what happens next following the merger, but it is expected that both companies will work towards integrating their operations and aligning their business strategies.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





